4D Molecular Therapeutics Inc Ordinary Shares FDMT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
4DMT Announces New Employment Inducement Grants
-
4DMT to Host Investor Day on October 21, 2026
-
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
-
4DMT Announces New Employment Inducement Grants
-
4DMT to Participate in Upcoming Investor Conferences
-
4DMT Announces New Employment Inducement Grants
-
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
-
4D Molecular Shares Rise Premarket on Partnership With Otsuka
Trading Information
- Previous Close Price
- $11.85
- Day Range
- $10.68–11.75
- 52-Week Range
- $6.96–16.93
- Bid/Ask
- $10.80 / $10.99
- Shares Outstanding
- 55.24M
- Market Cap
- $596.64M
- Volume/Avg
- 996,140 / 965,835
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.58
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 196
Valuation
|
Metric
|
FDMT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.46 |
Price/Sales | 7.58 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
FDMT
|
|---|---|
Quick Ratio | 7.68 |
Current Ratio | 8.03 |
Interest Coverage | — |
Quick Ratio
FDMT
Profitability
|
Metric
|
FDMT
|
|---|---|
Return on Assets (Normalized) | −32.13% |
Return on Equity (Normalized) | −36.82% |
Return on Invested Capital (Normalized) | −38.76% |
Return on Assets
FDMT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|d>c<CgQ | LOCK|wyH^ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%Jmgd$ | LOCK|?G!% | $83B | |||
| Moderna Inc
MRNA
| LOCK|?!pT!^$ | LOCK|Xkp | $80B | |||
| argenx SE ADR
ARGX
| LOCK|<SbTz@ | LOCK|f^ | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$^P$lwG | LOCK|H?? | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$><R!v^ | LOCK|<kNw | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^?s!rQb | LOCK|@>Zj | $28B | |||
| Incyte Corp
INCY
| LOCK|l<m&t<! | LOCK|&?c | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|<blJ$L | LOCK|%r@ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|$!M>sR | LOCK|gz< | $14B |
United States